Research Analysts Set Expectations for Genelux Q1 Earnings

Genelux Co. (NASDAQ:GNLX) – Stock analysts at Brookline Capital Management issued their Q1 2025 EPS estimates for Genelux in a report released on Tuesday, March 25th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.20) per share for the quarter. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.16) EPS and Q4 2025 earnings at ($0.16) EPS.

Genelux (NASDAQ:GNLX) last issued its earnings results on Friday, April 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.07).

Separately, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Genelux in a report on Tuesday. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $18.25.

Genelux Stock Up 1.7 %

NASDAQ GNLX opened at $3.08 on Thursday. Genelux has a 52 week low of $1.60 and a 52 week high of $6.50. The business has a 50 day moving average price of $4.06 and a 200-day moving average price of $3.10. The company has a market cap of $106.38 million, a price-to-earnings ratio of -3.24 and a beta of -1.41.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of GNLX. XTX Topco Ltd purchased a new stake in Genelux in the 3rd quarter valued at $59,000. Geode Capital Management LLC grew its stake in shares of Genelux by 39.7% in the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock worth $749,000 after acquiring an additional 89,854 shares in the last quarter. Apollon Wealth Management LLC raised its holdings in shares of Genelux by 20.4% in the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after purchasing an additional 2,857 shares during the last quarter. D.A. Davidson & CO. bought a new position in shares of Genelux during the fourth quarter valued at about $51,000. Finally, LifeSteps Financial Inc. boosted its holdings in Genelux by 11.1% during the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock worth $205,000 after purchasing an additional 8,715 shares during the last quarter. Institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.